BioNTech has reported a net loss of €807.8m, or €3.36 per diluted share, for the second quarter ended 30 June 2024, compared to a net loss of €190.4m, or €0.79 per diluted share, for the respective quarter in 2023.
The biotechnology firm reported a net loss of €315.1m, or €1.31 per diluted share, for the first quarter of 2024 (Q1 2024).
The German company reported revenues of €128.7m for the second quarter of 2024 (Q2 2024), a 23% decline compared to €167.7m for the same quarter in 2023, and a 31% decline compared to €187.6m for Q1 2024.
BioNTech reported a loss before tax of €805.8m for Q2 2024, compared to a loss before tax of €412.2m for the same period in the previous year.
The biotechnology company attributed the fall in net revenues to a decline in sales of its Covid-19 vaccines, due to a continued shift in demand from a pandemic to a seasonal endemic.
BioNTech CEO and co-founder Ugur Sahin said: “The year-to-date has been marked by significant data updates across our oncology portfolio.
These readouts reinforce the potential of our platform technologies, including our individualised and off-the-shelf mRNA vaccine platforms, iNeST and FixVac.
“We have also advanced our strategy by initiating clinical trials evaluating novel combinations of synergistic drug candidates.
BioNTech reported a net loss of €1.12bn, or €4.67m per diluted share, for the six months ended 30 June 2024, compared to a net profit of €311.8m, or €1.28 per diluted share, for the same period in 2023.
The biotech company reported total revenues of €316.3m for the first half of 2024 (H1 2024), a 78% decline compared to €1.44bn for the respective period in the previous year.
The German company reported an operating loss of €1.47bn for H1 2024, compared to an operating income of €91.1m for the same period in 2023.
BioNTech has reported a loss before tax of €1.13bn for H1 2024, compared to a profit before tax of €295.5m for the respective period in the previous year.
Sahin added: “We dosed the first patient in a trial evaluating the combination of the TROP2 antibody-drug conjugate BNT325/DB-1305 and the PD-L1-VEGF-A bispecific BNT327/PM8002.
“In addition, we have started commercialising variant-adapted Covid-19 vaccines for the upcoming season, while accelerating our clinical development efforts to realise the full potential of our technologies.”
